

Medical Policy

Zolgensma (Onasemnogene Apeparvovec)

Policy Number: 060

| | Commercial and Qualified Health Plans | MassHealth |
|----------------------------|---------------------------------------|------------|
| Authorization required | X | X |
| Authorization not required | | |

Overview

Zolgensma is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

Criteria (Commercial)

1. Criteria for Approval (The member must meet **all** of the following requirements):
 - Member has confirmed and symptomatic genetic diagnosis documented by bi-allelic mutations in the SMN1 gene AND three or less copies of SMN2 gene
 - Member has an anti-adeno-associated viral vector, serotype 9 (AAV9) antibody titer less than or equal to 1:50
 - Member is less than 2 years of age
 - Member has not previously received Zolgensma
 - Member does not have concomitant illness such as severe kidney or liver disease, active viral infection, or symptomatic cardiomyopathy
 - If the member is receiving treatment with Spinraza, that treatment will be discontinued
2. Dosing and Administration
 - Member will receive a single-dose Zolgensma intravenously infusion within accordance of the FDA approved labeling; 1.1×10^{14} vector genomes (vg) per kilogram of body weight.
3. Duration of Therapy
 - Single-dose one-time intravenous infusion per lifetime
4. Exclusions
 - The member has advanced SMA as evidenced but not limited to complete paralysis of limbs, invasive ventilatory support (tracheostomy), or use of non-invasive respiratory support for more than 16 hours per day.

Criteria (MassHealth)

For its MassHealth members Mass General Brigham Health Plan follows the Zolgensma clinical guidelines as set forth in MassHealth's Drug Utilization Review Program.

1. Criteria for Approval (The member must meet **all** of the following requirements as outlined in documentation provided by the treating prescriber):
 - Appropriate diagnosis (Type 1, 2 or 3 SMA)
 - A genetic test confirming the member has a diagnosis of bi-allelic mutation in the SMA1 gene (e.g. SMN1 homozygous gene deletion or mutation or compound heterozygous mutation)
 - A genetic test confirming the member has two or three copies of the SMN2 gene

- Member has an anti-adenoviral vector, serotype 9 (AAV9) antibody titer less than or equal to 1:50
- Member is less than 2 years of age

2. Dosing and Administration

- The prescriber is a neuromuscular specialist
- Member will receive a single-dose Zolgensma intravenously infusion within accordance of the FDA approved labeling; 1.1×10^{14} vector genomes (vg) per kilogram of body weight.

3. Duration of Therapy

- Single-dose one-time intravenous infusion per lifetime

4. Exclusions

- The member has advanced SMA as evidenced but not limited to complete paralysis of limbs, invasive ventilatory support (endotracheal tube or tracheotomy tube) or use of non-invasive respiratory assistance for at least 14 days for at least 16 hours per day.

Codes

| Authorized Code | Code Description |
|-----------------|--|
| J3399 | Injection, Onasemnogene abeparvovec-xioi, per treatment, up to 5×10^{15} vector genomes |

Effective

October 2022: Annual update. References updated.

October 2021: Annual update. References updated.

October 2020: Annual update. References updated.

July 2020: Added code.

April 1, 2020: Updated table and added Criteria section to reflect MassHealth coverage.

December 2019: Effective date.

References

Al-Zaidy S, Pickard AS, Kotha K, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. *Pediatric Pulmonology* 2018;54:179–185.

Chand D, Mohr F, McMillan H, et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. *J Hepatol.* 2021 Mar;74(3):560-566. doi: 10.1016/j.jhep.2020.11.001. Epub 2020 Nov 10. PMID: 33186633.

Friese J, Geitmann S, Holzwarth D, Müller N, et al. Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience. *J Neuromuscul Dis.* 2021;8(2):209-216. doi: 10.3233/JND-200593. PMID: 33427694; PMCID: PMC8075402.

Institute for Clinical and Evidence Review. Spinraza and Zolgensma for Spinal Muscular Atrophy: Effectiveness and Value (Final Evidence Report April 3, 2019; Updated May 24, 2019). 2019; https://icer-review.org/wp-content/uploads/2018/07/ICER_SMA_Final_Evidence_Report_052419.pdf. Accessed September 15, 2020

Kichula EA, Proud CM, Farrar MA, et al. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. *Muscle Nerve.* 2021 Oct;64(4):413-427. doi: 10.1002/mus.27363. Epub 2021 Jul 20. PMID: 34196026; PMCID: PMC8518380.

Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. *N Engl J Med.* 2017;377:1713-22



Mendell JR, Al-Zaidy S, Shell R, et al. AVXS-101 Phase 1 gene-replacement therapy clinical trial in SMA type 1: 24-month event-free survival and achievement of developmental milestones. Poster presented at: The 23rd International Annual Congress of the World Muscle Society, Mendoza, Argentina, October 2–6, 2018.

Muscular Dystrophy Association. Spinal Muscular Atrophy. n.d.; <https://www.mda.org/disease/spinalmuscular-atrophy>. Accessed March 12, 2020

Saffari A, Kölker S et.al. Novel challenges in spinal muscular atrophy – How to screen and whom to treat? *Annals of Clinical and Translational Neurology* 2019; 6(1): 197–205

Stevens D, Claborn MK, Gildon BL, et al. Onasemnogene beparovect-xioi: Gene therapy for spinal muscular atrophy. *AnnPharmacother*. 2020 Mar 23 [Epub ahead of print].

Waldrop MA, Karingada C, Storey MA, Powers B, Iammarino MA, Miller NF, Alfano LN, Noritz G, Rossman I, Ginsberg M, Mosher KA, Broomall E, Goldstein J, Bass N, Lowes LP, Tsao CY, Mendell JR, Connolly AM. Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes. *Pediatrics*. 2020 Sep;146(3):e20200729. doi: 10.1542/peds.2020-0729. PMID: 32843442.

Zolgensma [package insert]. Bannockburn, IL; AveXis, Inc. May 2019.

